BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF, Wood CG. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010;116:3378-3388. [PMID: 20564061 DOI: 10.1002/cncr.25046] [Cited by in Crossref: 134] [Cited by in F6Publishing: 123] [Article Influence: 11.2] [Reference Citation Analysis]
Number Citing Articles
1 Silberstein JL, Adamy A, Maschino AC, Ehdaie B, Garg T, Favaretto RL, Ghoneim TP, Motzer RJ, Russo P. Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC). BJU Int 2012;110:1276-82. [PMID: 22554107 DOI: 10.1111/j.1464-410X.2012.11103.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
2 Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, Kapoor A, Karam J, Kauffmann C, Klatte T, Ljungberg B, Matin S, Sjoberg D, Staehler M, Stewart GD, Tanguay S, Uzzo R, Welsh S, Wood L, Wood C, Bex A. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. World J Urol 2018;36:1973-80. [PMID: 30069581 DOI: 10.1007/s00345-018-2427-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
3 Marko J, Craig R, Nguyen A, Udager AM, Wolfman DJ. Chromophobe Renal Cell Carcinoma with Radiologic-Pathologic Correlation. Radiographics 2021;41:1408-19. [PMID: 34388049 DOI: 10.1148/rg.2021200206] [Reference Citation Analysis]
4 Marchioni M, Kriegmair M, Heck M, Amiel T, Porpiglia F, Ceccucci E, Campi R, Minervini A, Mari A, Van Bruwaene S, Linares E, Hevia V, Musquera M, D'Anna M, Derweesh I, Bradshaw A, Autorino R, Guruli G, Veccia A, Roussel E, Albersen M, Pavan N, Claps F, Antonelli A, Palumbo C, Klatte T, Erdem S, Mir MC; in collaboration with EAU-Young Academic Urologist Kidney Cancer Group. Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC). Eur Urol Oncol 2021;4:256-63. [PMID: 33384274 DOI: 10.1016/j.euo.2020.12.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Lee LS, Tan M. Predictive models for the practical management of renal cell carcinoma. Nat Rev Urol 2012;9:73-84. [DOI: 10.1038/nrurol.2011.224] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
6 Bex A, Ljungberg B, van Poppel H, Powles T; European Association of Urology. The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016. Eur Urol 2016;70:901-5. [PMID: 27445002 DOI: 10.1016/j.eururo.2016.07.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
7 Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, Abel EJ, Culp SH, Tamboli P, Wood CG. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol 2013;63:947-52. [PMID: 23273681 DOI: 10.1016/j.eururo.2012.11.040] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 5.4] [Reference Citation Analysis]
8 Delacroix SE Jr, Chapin BF, Wood CG. The role of lymph node dissection in renal cell carcinoma. Urol Clin North Am 2011;38:419-28, vi. [PMID: 22045173 DOI: 10.1016/j.ucl.2011.07.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
9 Xia L, Strother MC, Taylor BL, Chelluri RR, Pulido JE, Guzzo TJ. Hospital volume and short-term outcomes after cytoreductive nephrectomy. J Surg Oncol 2018;117:1589-96. [PMID: 29575038 DOI: 10.1002/jso.25047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Kus T, Aktas G, Sevinc A, Oktay C, Kalender ME, Camci C. Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer. Mol Clin Oncol 2016;4:290-2. [PMID: 26893877 DOI: 10.3892/mco.2015.677] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Culp SH. Reconciling the use of cytoreductive nephrectomy in the targeted therapy era. Eur Urol 2014;66:711-2. [PMID: 25001889 DOI: 10.1016/j.eururo.2014.06.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Crispen PL, Blute ML. Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma. Curr Urol Rep 2012;13:38-46. [PMID: 22105577 DOI: 10.1007/s11934-011-0225-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
13 Culp SH. Cytoreductive nephrectomy and its role in the present-day period of targeted therapy. Ther Adv Urol 2015;7:275-85. [PMID: 26425142 DOI: 10.1177/1756287215585501] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
14 Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, Sverrisson EF, Spiess PE, Gupta S, Poch MA, Sexton WJ. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer 2015;13:225-30. [PMID: 25544725 DOI: 10.1016/j.clgc.2014.12.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
15 Puente Vázquez J, Alonso Gordoa T, Moreno J, Poma L, Diaz Rubio E, Gomez A, Blazquez J, Gonzalez Larriba JL. New Challenges in Kidney Cancer Management: Integration of Surgery and Novel Therapies. Curr Treat Options in Oncol 2015;16. [DOI: 10.1007/s11864-015-0337-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
16 De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L, van Melick HE, Aarts MJ, Lattouf JB, Powles T, De Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen JB, Bex A. Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME). European Urology 2019;76:437-40. [DOI: 10.1016/j.eururo.2019.06.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
17 Culp SH, Karam JA, Wood CG. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era. Urologic Oncology: Seminars and Original Investigations 2014;32:561-8. [DOI: 10.1016/j.urolonc.2013.12.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
18 Heidenreich A, Pfister D, Porres D. [Radical cancer surgery of renal cell and prostate carcinoma with hematogenous metastasis: benefits]. Urologe A 2014;53:823-31. [PMID: 24824471 DOI: 10.1007/s00120-014-3519-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Black PC. Radical locoregional therapy for bladder cancer: underutilized, or unsuitable in many? Eur Urol 2013;63:830-1. [PMID: 23317935 DOI: 10.1016/j.eururo.2012.12.061] [Reference Citation Analysis]
20 Shinder BM, Rhee K, Farrell D, Farber NJ, Stein MN, Jang TL, Singer EA. Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. Front Oncol. 2017;7:107. [PMID: 28620578 DOI: 10.3389/fonc.2017.00107] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
21 Ohno Y, Nakashima J, Ohori M, Tanaka A, Hashimoto T, Gondo T, Hatano T, Tachibana M. Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status. Int J Clin Oncol 2014;19:139-45. [DOI: 10.1007/s10147-012-0514-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
22 Tilki D, Hu B, Nguyen HG, Dall’era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-salamanca JI, Master VA, Matloob R, Mckiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of Synchronous Metastasis Distribution on Cancer Specific Survival in Renal Cell Carcinoma after Radical Nephrectomy with Tumor Thrombectomy. Journal of Urology 2015;193:436-42. [DOI: 10.1016/j.juro.2014.07.087] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
23 Noe A, de Bruijn RE, Blank C, Horenblas S, Haanen J, Bex A. Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. World J Urol 2016;34:1067-72. [PMID: 26832350 DOI: 10.1007/s00345-016-1769-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
24 Kotecha RR, Motzer RJ, Voss MH. Towards individualized therapy for metastatic renal cell carcinoma. Nat Rev Clin Oncol 2019;16:621-33. [PMID: 30992569 DOI: 10.1038/s41571-019-0209-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 15.3] [Reference Citation Analysis]
25 La Rochelle J, Wood C, Bex A. Refining the Use of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma. Seminars in Oncology 2013;40:429-35. [DOI: 10.1053/j.seminoncol.2013.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
26 Kokorovic A, Rendon RA. Cytoreductive nephrectomy in metastatic kidney cancer: what do we do now? Current Opinion in Supportive & Palliative Care 2019;13:255-61. [DOI: 10.1097/spc.0000000000000433] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Sheng X, Lu X, Wu J, Chen L, Cao H. A Nomogram Predicting the Prognosis of Renal Cell Carcinoma Patients with Lung Metastases. Biomed Res Int 2021;2021:6627562. [PMID: 33791367 DOI: 10.1155/2021/6627562] [Reference Citation Analysis]
28 McIntosh AG, Umbreit EC, Holland LC, Gu C, Tannir NM, Matin SF, Karam JA, Culp SH, Wood CG. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. Cancer 2020;126:3950-60. [PMID: 32515845 DOI: 10.1002/cncr.32991] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
29 Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, Joly F, Guy L, Ravaud A, Azzouzi AR, Gravis G, Chevreau C, Zini L, Lang H, Pfister C, Lechevallier E, Fais PO, Berger J, Vayleux B, Roupret M, Audenet F, Descazeaud A, Rigaud J, Machiels JP, Staehler M, Salomon L, Ferriere JM, Kleinclauss F, Bensalah K, Patard JJ. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol 2015;33:339.e9-15. [PMID: 26087971 DOI: 10.1016/j.urolonc.2015.05.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
30 Cho IC, Chung J. Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol 2012;53:217-28. [PMID: 22536463 DOI: 10.4111/kju.2012.53.4.217] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
31 Manley BJ, Kim EH, Vetter JM, Potretzke AM, Strope SA. Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA. Int Braz J Urol 2017;43:432-9. [PMID: 28128914 DOI: 10.1590/S1677-5538.IBJU.2015.0118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
32 Tatsugami K, Shinohara N, Kondo T, Yamasaki T, Eto M, Tsushima T, Terachi T, Naito S; the Japanese Society of Renal Cancer. Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era: Cytoreductive nephrectomy for Japanese patients. Int J Urol 2015;22:736-40. [DOI: 10.1111/iju.12803] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
33 Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ, Powles T, Bex A. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. European Urology 2019;75:111-28. [DOI: 10.1016/j.eururo.2018.09.016] [Cited by in Crossref: 62] [Cited by in F6Publishing: 70] [Article Influence: 20.7] [Reference Citation Analysis]
34 Shapiro DD, Westerman ME, Karam JA, Wood CG. Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease: Have We Finally Answered the Question? Cancer J 2020;26:382-9. [PMID: 32947306 DOI: 10.1097/PPO.0000000000000470] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 DiNatale RG, Xie W, Becerra MF, Silagy AW, Attalla K, Sanchez A, Mano R, Marcon J, Blum KA, Benfante NE, Voss MH, Motzer RJ, Coleman J, Choueiri TK, Reznik E, Russo P, Heng DYC, Hakimi AA. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. Eur Urol Oncol 2020;3:47-56. [PMID: 31735646 DOI: 10.1016/j.euo.2019.10.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
36 Aslam MZ, Matthews PN. Cytoreductive nephrectomy for metastatic renal cell carcinoma: a review of the historical literature and its role in the era of targeted molecular therapy. ISRN Urol 2014;2014:717295. [PMID: 24587921 DOI: 10.1155/2014/717295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
37 Larcher A, Wallis CJ, Bex A, Blute ML, Ficarra V, Mejean A, Karam JA, Van Poppel H, Pal SK. Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates? European Urology Oncology 2019;2:365-78. [DOI: 10.1016/j.euo.2019.04.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 8.7] [Reference Citation Analysis]
38 Trinh QD, Bianchi M, Hansen J, Tian Z, Abdollah F, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI, Sun M. In-hospital mortality and failure to rescue after cytoreductive nephrectomy. Eur Urol 2013;63:1107-14. [PMID: 22981674 DOI: 10.1016/j.eururo.2012.08.069] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
39 Ghandour RA, Singla N, Margulis V. The use of cytoreductive nephrectomy in patients with renal cell carcinoma. Expert Rev Anticancer Ther 2019;19:405-11. [PMID: 31020871 DOI: 10.1080/14737140.2019.1606716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Krabbe LM, Haddad AQ, Westerman ME, Margulis V. Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World J Urol 2014;32:615-22. [PMID: 24700309 DOI: 10.1007/s00345-014-1286-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
41 Considine B, Hurwitz ME. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma. Curr Oncol Rep 2019;21:34. [PMID: 30848378 DOI: 10.1007/s11912-019-0779-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
42 Zhang J, Yao YH, Li BG, Yang Q, Zhang PY, Wang HT. Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep 2015;5:9800. [PMID: 25902419 DOI: 10.1038/srep09800] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 7.9] [Reference Citation Analysis]
43 Silagy AW, Kotecha RR, Weng S, Holmes A, Singla N, Mano R, Attalla K, Weiss KL, DiNatale RG, Patil S, Coleman JA, Motzer RJ, Russo P, Voss MH, Hakimi AA. Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer 2021. [PMID: 34286865 DOI: 10.1002/cncr.33790] [Reference Citation Analysis]
44 Lyon TD, Gershman B, Shah PH, Thompson RH, Boorjian SA, Lohse CM, Costello BA, Cheville JC, Leibovich BC. Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era. Urol Oncol 2018;36:499.e1-7. [PMID: 30228096 DOI: 10.1016/j.urolonc.2018.08.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
45 Hsiang WR, Kenney PA, Leapman MS. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. Curr Oncol Rep 2020;22:35. [PMID: 32170461 DOI: 10.1007/s11912-020-0895-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Psutka SP, Kim SP, Gross CP, Van Houten H, Thompson RH, Abouassaly R, Weight C, Boorjian SA, Leibovich BC, Shah ND. The Impact of Targeted Therapy on Management of Metastatic Renal Cell Carcinoma: Trends in Systemic Therapy and Cytoreductive Nephrectomy Utilization. Urology 2015;85:442-51. [DOI: 10.1016/j.urology.2014.10.040] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
47 Kim DY, Wood CG, Karam JA. Treating the two extremes in renal cell carcinoma: management of small renal masses and cytoreductive nephrectomy in metastatic disease. Am Soc Clin Oncol Educ Book 2014;:e214-21. [PMID: 24857105 DOI: 10.14694/EdBook_AM.2014.34.e214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
48 Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar-shoshtari K, Borregales LD, Sexton WJ, Patil D, Matin SF, Wood CG, Karam JA. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. Journal of Urology 2017;198:281-8. [DOI: 10.1016/j.juro.2017.03.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
49 Capitanio U, Abdollah F, Matloob R, Salonia A, Suardi N, Briganti A, Carenzi C, Rigatti P, Montorsi F, Bertini R. Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: Implications for multimodal therapy: Metastatic renal cell carcinoma. Int J Urol 2013;20:572-9. [DOI: 10.1111/iju.12004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
50 Corcoran AT, Kaffenberger SD, Clark PE, Walton J, Handorf E, Piotrowski Z, Tomaszewski JJ, Ginzburg S, Mehrazin R, Plimack E, Chen DY, Smaldone MC, Uzzo RG, Morgan TM, Kutikov A. Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. BJU Int 2015;116:351-7. [PMID: 25123843 DOI: 10.1111/bju.12897] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
51 Adamy A. Editorial comment. Urology 2014;84:1419. [PMID: 25475228 DOI: 10.1016/j.urology.2014.05.079] [Reference Citation Analysis]
52 Hatzaras I, Gleisner AL, Pulitano C, Sandroussi C, Hirose K, Hyder O, Wolfgang CL, Aldrighetti L, Crawford M, Choti MA, Pawlik TM. A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB (Oxford). 2012;14:532-538. [PMID: 22762401 DOI: 10.1111/j.1477-2574.2012.00495.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
53 Takagi T, Sugihara T, Yasunaga H, Horiguchi H, Fushimi K, Kondo T, Homma Y, Tanabe K. Cytoreductive nephrectomy for metastatic renal cell carcinoma: A population-based analysis of perioperative outcomes according to clinical stage: CN for metastatic kidney cancer. Int J Urol 2014;21:770-5. [DOI: 10.1111/iju.12446] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
54 Kalapara AA, Frydenberg M. The role of open radical nephrectomy in contemporary management of renal cell carcinoma. Transl Androl Urol 2020;9:3123-39. [PMID: 33457285 DOI: 10.21037/tau-19-327] [Reference Citation Analysis]
55 Dariane C, Timsit MO, Méjean A. Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift? Bull Cancer 2018;105 Suppl 3:S229-34. [PMID: 30595151 DOI: 10.1016/S0007-4551(18)30377-1] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
56 Sierra PS, Cordeiro MD, Albuquerque EV, Bastos DA, Bonadio RC, Sarkis AS, Cavalcante A, Pontes J Jr, Coelho RF, Nahas WC. Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era. Clin Genitourin Cancer 2020;18:e134-44. [PMID: 31980410 DOI: 10.1016/j.clgc.2019.09.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Bhanvadia S, Pal SK. Cytoreductive nephrectomy: questions remain after CARMENA. Nat Rev Urol 2018;15:530-2. [PMID: 30054576 DOI: 10.1038/s41585-018-0064-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
58 Choi CI, Kang M, Sung HH, Jeon HG, Jeong BC, Jeon SS, Lee HM, Seo SIL. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience. Clin Genitourin Cancer 2018;16:e1189-99. [PMID: 30262447 DOI: 10.1016/j.clgc.2018.07.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Shapiro DD, Abel EJ. Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors. Current Opinion in Urology 2019;29:513-20. [DOI: 10.1097/mou.0000000000000658] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
60 Silagy AW, Attalla K, Dinatale RG, Weiss KL, Weng S, Mano R, Iosepovici S, Marcon J, Reznik E, Kotecha RR, Motzer RJ, Voss MH, Coleman JA, Hakimi AA, Russo P. A qualitative framework of non-selection factors for cytoreductive nephrectomy. World J Urol 2021. [PMID: 33779820 DOI: 10.1007/s00345-021-03650-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Biles MJ, Patel HD, Allaf ME. Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors. Urol Clin North Am 2020;47:359-70. [PMID: 32600537 DOI: 10.1016/j.ucl.2020.04.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
62 Silagy AW, Mano R, Blum KA, DiNatale RG, Marcon J, Tickoo SK, Reznik E, Coleman JA, Russo P, Hakimi AA. The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. Urology 2020;136:169-75. [PMID: 31726184 DOI: 10.1016/j.urology.2019.08.058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
63 Psutka SP. Personalizing preoperative risk stratification and refining patient selection for cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer 2020;126:3912-5. [PMID: 32515836 DOI: 10.1002/cncr.32993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
64 Guo B, Liu S, Wang M, Hou H, Liu M. The role of cytoreductive nephrectomy in renal cell carcinoma patients with liver metastasis. Bosn J Basic Med Sci 2021;21:229-34. [PMID: 32767963 DOI: 10.17305/bjbms.2020.4896] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
65 Liu KG, Gupta S, Goel S. Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. Oncotarget 2017;8:17313-27. [PMID: 28061473 DOI: 10.18632/oncotarget.14388] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
66 Hou G, Li X, Zheng Y, Liu P, Yan F, Ju D, Zhang G, Zheng W, Gao M, Hou N, Yuan J, Wang F, Yuan J. Construction and validation of a novel prognostic nomogram for patients with sarcomatoid renal cell carcinoma: a SEER-based study. Int J Clin Oncol 2020;25:1356-63. [PMID: 32361824 DOI: 10.1007/s10147-020-01681-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
67 Mckiernan J, Wood CG. Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Journal of Urology 2013;190:386-8. [DOI: 10.1016/j.juro.2013.05.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
68 Trinh Q, Sukumar S, Schmitges J, Bianchi M, Sun M, Shariat SF, Sammon JD, Jeldres C, Zorn KC, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI. Effect of Nodal Metastases on Cancer-specific Mortality After Cytoreductive Nephrectomy. Ann Surg Oncol 2013;20:2096-102. [DOI: 10.1245/s10434-012-2806-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
69 Sakai I, Miyake H, Hinata N, Fujisawa M. Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy. Int J Clin Oncol 2014;19:674-8. [DOI: 10.1007/s10147-013-0612-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
70 Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol 2018;36:1943-52. [PMID: 29713755 DOI: 10.1007/s00345-018-2309-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 56] [Article Influence: 11.8] [Reference Citation Analysis]
71 Tam E, Neculiseanu E, Sidhu G. Refractory Renal Cell Cancer with Gastro-renal Fistula: A Rare Complication. Cureus 2020;12:e6580. [PMID: 32051793 DOI: 10.7759/cureus.6580] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Chatzizacharias NA, Rosich-Medina A, Dajani K, Harper S, Huguet E, Liau SS, Praseedom RK, Jah A. Surgical management of hepato-pancreatic metastasis from renal cell carcinoma. World J Gastrointest Oncol 2017; 9(2): 70-77 [PMID: 28255428 DOI: 10.4251/wjgo.v9.i2.70] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
73 Zhao K, Kim EH, Vetter JM, Hsieh JJ, Venkatesh R, Bhayani SB, Figenshau RS. Laparoscopic cytoreductive nephrectomy is associated with significantly improved survival compared with open cytoreductive nephrectomy or targeted therapy alone. Mol Clin Oncol 2020;13:71. [PMID: 33005405 DOI: 10.3892/mco.2020.2141] [Reference Citation Analysis]
74 You D, Jeong IG, Song C, Lee J, Hong B, Hong JH, Ahn H, Kim C. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era. Japanese Journal of Clinical Oncology 2014;45:96-102. [DOI: 10.1093/jjco/hyu171] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
75 Grassi P, Verzoni E, Porcu L, Testa I, Iacovelli R, Torri V, Braud Fd, Procopio G. Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. Future Oncol 2014;10:1361-72. [PMID: 25052747 DOI: 10.2217/fon.14.69] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
76 Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Dzyuba-Negrean C, Shariat SF, Saad F, Simeone C, Berruti A, Briganti A, Kapoor A, Antonelli A, Karakiewicz PI. Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 2020;18:e730-8. [PMID: 32800473 DOI: 10.1016/j.clgc.2020.05.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Psutka SP, Chang SL, Cahn D, Uzzo RG, Mcgregor BA. Reassessing the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in 2019. American Society of Clinical Oncology Educational Book 2019. [DOI: 10.1200/edbk_237453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
78 Kenney PA, Wood CG. Integration of surgery and systemic therapy for renal cell carcinoma. Urol Clin North Am. 2012;39:211-231, vii. [PMID: 22487764 DOI: 10.1016/j.ucl.2012.01.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
79 Westerman ME, Shapiro DD, Tannir NM, Campbell MT, Matin SF, Karam JA, Wood CG. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int 2020;126:745-53. [PMID: 32623821 DOI: 10.1111/bju.15160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
80 Thomas AZ, Adibi M, Borregales LD, Karam JA, Wood CG. Cytoreductive surgery in the era of targeted molecular therapy. Transl Androl Urol. 2015;4:301-309. [PMID: 26815334 DOI: 10.3978/j.issn.2223-4683.2015.04.09] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
81 Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol. 2011;60:1273-1279. [PMID: 21784574 DOI: 10.1016/j.eururo.2011.07.008] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
82 Abern MR, Tsivian M, Polascik TJ, Coogan CL. Characteristics and outcomes of tumors arising from the distal nephron. Urology 2012;80:140-6. [PMID: 22626576 DOI: 10.1016/j.urology.2012.03.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
83 Peyton CC, Abel EJ, Chipollini J, Boulware DC, Azizi M, Karam JA, Margulis V, Master VA, Matin SF, Raman JD, Sexton WJ, Wood CG, Spiess PE. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus 2020;6:104-11. [PMID: 30206003 DOI: 10.1016/j.euf.2018.08.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
84 Umbreit EC, McIntosh AG, Suk-Ouichai C, Karam JA, Wood CG. The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma. Indian J Urol 2021;37:13-9. [PMID: 33850351 DOI: 10.4103/iju.IJU_293_20] [Reference Citation Analysis]
85 Li H, Samawi H, Heng DY. The use of prognostic factors in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2015;33:509-16. [DOI: 10.1016/j.urolonc.2015.08.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
86 Dizman N, Maia MC, Pal SK. Cytoreductive nephrectomy: A medical oncologist's perspective. Urol Oncol 2017;35:180-2. [PMID: 29037531 DOI: 10.1016/j.urolonc.2017.03.018] [Reference Citation Analysis]
87 Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, Marconi L, Merseburger AS, Fernández-pello S, Tahbaz R, Abu-ghanem Y, Staehler M, Volpe A, Powles T. Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. European Urology 2018;74:805-9. [DOI: 10.1016/j.eururo.2018.08.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
88 Manley BJ, Tennenbaum DM, Vertosick EA, Hsieh JJ, Sjoberg DD, Assel M, Benfante NE, Strope SA, Kim E, Casuscelli J, Becerra MF, Coleman JA, Hakimi AA, Russo P. The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models. Urol Oncol 2017;35:35.e1-5. [PMID: 27567689 DOI: 10.1016/j.urolonc.2016.07.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
89 Wasserman M, Sobel D, Pareek G. Choice of Surgical Options in Kidney Cancer and Surgical Complications. Semin Nephrol 2020;40:42-8. [PMID: 32130965 DOI: 10.1016/j.semnephrol.2019.12.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
90 Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, Barni S. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol 2015;54:961-70. [PMID: 25984930 DOI: 10.3109/0284186X.2015.1043026] [Cited by in Crossref: 107] [Cited by in F6Publishing: 70] [Article Influence: 15.3] [Reference Citation Analysis]
91 Tong E, Keyes K, Charles RM, Eyzaguirre E, Williams SB. A 57-year-old Woman With Hematuria and Headaches. Urology 2017;102:17-20. [PMID: 27845217 DOI: 10.1016/j.urology.2016.11.009] [Reference Citation Analysis]
92 Graves A, Hessamodini H, Wong G, Lim WH. Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther. 2013;2:73-90. [PMID: 27471690 DOI: 10.2147/itt.s31426] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
93 Esdaille AR, Abel EJ. Evolution of risk stratification systems is critical for improving patient selection for cytoreductive nephrectomy. Cancer 2021. [PMID: 34286855 DOI: 10.1002/cncr.33788] [Reference Citation Analysis]
94 Du Y, Pahernik S, Hadaschik B, Teber D, Duensing S, Jäger D, Hohenfellner M, Grüllich C. Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis. Urologic Oncology: Seminars and Original Investigations 2016;34:433.e1-8. [DOI: 10.1016/j.urolonc.2016.05.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
95 Silagy AW, Flynn J, Mano R, Blum KA, Marcon J, DiNatale RG, Sanchez A, Carlo MI, Motzer RJ, Coleman JA, Russo P, Ostrovnaya I, Chen YB, Hakimi AA. Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Urol Oncol 2019;37:811.e9-811.e16. [PMID: 31521530 DOI: 10.1016/j.urolonc.2019.07.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
96 Rendon RA, Kapoor A, Breau R, Leveridge M, Feifer A, Black PC, So A. Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus. Can Urol Assoc J 2014;8:E398-412. [PMID: 25024794 DOI: 10.5489/cuaj.1894] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
97 González J, Gaynor JJ, Alameddine M, Esteban M, Ciancio G. Indications, complications, and outcomes following surgical management of locally advanced and metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2018;18:237-50. [PMID: 29353520 DOI: 10.1080/14737140.2018.1431530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
98 Karam JA, Wood CG. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. Hematol Oncol Clin North Am 2011;25:753-64. [PMID: 21763966 DOI: 10.1016/j.hoc.2011.05.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
99 Tabakin AL, Stein MN, Anderson CB, Drake CG, Singer EA. Cytoreductive nephrectomy for metastatic renal cell carcinoma, the ultimate urologic 'Choosing Wisely' campaign: a narrative review. Transl Cancer Res 2020;9:7337-49. [PMID: 33354523 DOI: 10.21037/tcr-20-2343] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
100 Drake R. Kidney cancer: Better surgery selection criteria. Nat Rev Urol 2010;7:592. [PMID: 21113998 DOI: 10.1038/nrurol.2010.173] [Reference Citation Analysis]
101 Dilme RV, Rivas JG, Campi R, Puente J, Jerez T, Enikeev D, Esperto F, Sierra JM. Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate? Curr Urol Rep 2021;22:54. [PMID: 34654989 DOI: 10.1007/s11934-021-01073-7] [Reference Citation Analysis]
102 Zhao Z, Wu W, Duan X, Zeng G, Liu Y. The value of cytoreductive nephrectomy on the survival of metastatic renal carcinoma patients based on the number of site-specific metastases. PLoS One 2019;14:e0215861. [PMID: 31013336 DOI: 10.1371/journal.pone.0215861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
103 Roussel E, Verbiest A, Milenkovic U, Van Cleynenbreugel B, Van Poppel H, Joniau S, Beuselinck B, Albersen M. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. Scandinavian Journal of Urology 2020;54:493-9. [DOI: 10.1080/21681805.2020.1814858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
104 Khochikar MV. Cytoreductive Surgery in the Management of Renal Tumours: Rationale, Current Evidence and Future Perspectives. Indian J Surg Oncol 2017;8:33-8. [PMID: 28127180 DOI: 10.1007/s13193-016-0592-3] [Reference Citation Analysis]
105 Blute ML, Ziemlewicz TJ, Lang JM, Kyriakopoulos C, Jarrard DF, Downs TM, Grimes M, Shi F, Mann MA, Abel EJ. Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology 2017;100:139-44. [DOI: 10.1016/j.urology.2016.09.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
106 Fukuda H, Takagi T, Kondo T, Yoshida K, Shimizu S, Nagashima Y, Tanabe K. Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy. Int J Clin Oncol 2018;23:539-46. [DOI: 10.1007/s10147-017-1221-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
107 Bex A, Powles T. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when. Expert Rev Anticancer Ther 2012;12:787-97. [PMID: 22716495 DOI: 10.1586/era.12.54] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
108 Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, de Velasco G, Trinh QD, Choueiri TK. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. J Clin Oncol 2016;34:3267-75. [PMID: 27325852 DOI: 10.1200/JCO.2016.66.7931] [Cited by in Crossref: 118] [Cited by in F6Publishing: 44] [Article Influence: 19.7] [Reference Citation Analysis]
109 Bex A, Haanen J. Do targeted agents offer clinical benefit as presurgical therapy? World J Urol 2014;32:3-8. [DOI: 10.1007/s00345-013-1041-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
110 Chapin BF, Delacroix SE Jr, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 2011;60:964-71. [PMID: 21621907 DOI: 10.1016/j.eururo.2011.05.032] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
111 Qi N, Wu P, Chen J, Li T, Ning X, Wang J, Gong K. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience. World J Surg Oncol 2017;15:4. [PMID: 28056988 DOI: 10.1186/s12957-016-1066-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
112 Patel HD, Karam JA, Allaf ME. Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy. JCO 2018;36:3601-7. [DOI: 10.1200/jco.2018.79.0246] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
113 Mano R, Gopal N, Hakimi AA. The evolving role of cytoreductive nephrectomy: incorporating genomics of metastatic renal cell carcinoma into treatment decisions. Curr Opin Urol 2019;29:531-9. [PMID: 31313716 DOI: 10.1097/MOU.0000000000000663] [Reference Citation Analysis]
114 Macleod LC, Odisho AY, Tykodi SS, Holt SK, Harper JD, Gore JL. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort. Urology 2018;113:146-52. [DOI: 10.1016/j.urology.2017.11.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
115 Sun M, Hanna N, Trinh QD, Choueiri TK. Reply to C. Buttigliero et al and B. Biswas et al. J Clin Oncol 2017;35:1266-7. [PMID: 28165905 DOI: 10.1200/JCO.2016.71.7249] [Reference Citation Analysis]
116 Sharma V, Thompson RH. Cytoreductive Nephrectomy in the Wake of CARMENA: When to Consider it. European Urology Oncology 2019;2:379-80. [DOI: 10.1016/j.euo.2019.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
117 Reaume MN, Basappa NS, Wood L, Kapoor A, Bjarnason GA, Blais N, Breau RH, Canil C, Cheung P, Conter HJ, Hotte SJ, Jeldres C, Jewett MAS, Karakiewicz PI, Kollmannsberger C, Patenaude F, So A, Soulières D, Venner P, Violette P, Zalewski P, Chappell H, North SA; Kidney Cancer Research Network of Canada. Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. Can Urol Assoc J 2017;11:310-20. [PMID: 29382441 DOI: 10.5489/cuaj.4769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
118 Nizam A, Schindelheim JA, Ornstein MC. The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer Treat Res Commun 2020;23:100169. [PMID: 32126518 DOI: 10.1016/j.ctarc.2020.100169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
119 Vourganti S, Shuch B, Bratslavsky G. Surgical management of large renal tumors. Expert Rev Anticancer Ther 2011;11:1889-900. [PMID: 22117156 DOI: 10.1586/era.11.129] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
120 Adibi M, Thomas AZ, Borregales LD, Matin SF, Wood CG, Karam JA. Surgical considerations for patients with metastatic renal cell carcinoma. Urol Oncol 2015;33:528-37. [PMID: 26546481 DOI: 10.1016/j.urolonc.2015.10.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
121 Hua KC, Hu YC. Establishment of predictive model for patients with kidney cancer bone metastasis: a study based on SEER database. Transl Androl Urol 2020;9:523-43. [PMID: 32420159 DOI: 10.21037/tau.2020.01.24] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
122 Lenis AT, Burton CS, Golla V, Pooli A, Faiena I, Johnson DC, Salmasi A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K. Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival. Urol Oncol 2019;37:577.e9-577.e16. [PMID: 30930099 DOI: 10.1016/j.urolonc.2019.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
123 Kim SH, Jeong KC, Joung JY, Seo HK, Lee KH, Chung J. Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis. Sci Rep 2018;8:2974. [PMID: 29445167 DOI: 10.1038/s41598-018-20822-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
124 Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong Md PhD IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol 2019;5:164-70. [PMID: 30543350 DOI: 10.1001/jamaoncol.2018.5543] [Cited by in Crossref: 132] [Cited by in F6Publishing: 147] [Article Influence: 44.0] [Reference Citation Analysis]
125 Barata PC, Rini BI. Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin. 2017;67:507-524. [PMID: 28961310 DOI: 10.3322/caac.21411] [Cited by in Crossref: 204] [Cited by in F6Publishing: 229] [Article Influence: 40.8] [Reference Citation Analysis]
126 Patel HD, Gorin MA, Gupta N, Kates M, Johnson MH, Pierorazio PM, Allaf ME. Mortality trends and the impact of lymphadenectomy on survival for renal cell carcinoma patients with distant metastasis. Can Urol Assoc J 2016;10:389-95. [PMID: 28096912 DOI: 10.5489/cuaj.1999] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
127 Balssa L, Kleinclauss F, Almotlak H, Thiery-Vuillemin A. [Cytoreduction nephrectomy: No future?]. Bull Cancer 2018;105:981-4. [PMID: 30336932 DOI: 10.1016/j.bulcan.2018.08.009] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
128 Zhang Z, Wu H, Yang T, Wu Y, Yu N, Xu Z. Metastatic renal cell carcinoma patients of T4 stage who are in status of N1 stage or older than 76 years cannot benefit from cytoreductive nephrectomy. BMC Cancer 2020;20:844. [PMID: 32883242 DOI: 10.1186/s12885-020-07351-w] [Reference Citation Analysis]
129 Kim EH, Potretzke AM, Figenshau RS, Perrino CM. Metastatic renal cell carcinoma presenting as a thyroid mass. J Urol 2015;193:677-8. [PMID: 25447100 DOI: 10.1016/j.juro.2014.11.012] [Reference Citation Analysis]